10.3 Medication Safety, Quality of Care, & Public Health

Medication Safety, Quality of Care, & Public Health

Ensuring medication safety and advancing public health are core responsibilities of the clinical pharmacist. The BCPS exam rigorously tests knowledge of error analysis methodologies, safety regulations, and foundational public health concepts, particularly immunizations.

Error Analysis and Quality Improvement

When adverse events occur, or when designing new clinical systems, specific methodologies are employed to analyze and mitigate risk.

Root Cause Analysis (RCA)

• Definition: A retrospective approach utilized after a medication error or sentinel event has occurred. The goal is to identify the underlying systemic causes that led to the error, rather than assigning individual blame.
• Process: Multidisciplinary teams reconstruct the event, ask "why" repeatedly (e.g., the "Five Whys" technique), and map out the sequence of events. The focus is on system vulnerabilities (e.g., look-alike/sound-alike packaging, flawed electronic health record alerts, inadequate staffing).
• Outcome: The implementation of corrective action plans (CAPs) designed to prevent recurrence. Strong actions (e.g., forcing functions, computerization) are prioritized over weak actions (e.g., staff education, new policies).

Failure Mode and Effects Analysis (FMEA)

• Definition: A prospective and proactive approach used to evaluate a new process or system before it is implemented, or to review a high-risk process before an error occurs.
• Process: A multidisciplinary team breaks down a process into specific steps, identifies how each step could fail (failure modes), determines the potential consequences (effects), and analyzes the causes of those failures.
• Outcome: The team assigns a risk priority number (RPN) based on the severity, probability of occurrence, and detectability of each failure mode. Processes are then redesigned to mitigate the highest-risk failure modes before they can harm a patient.

Medication Safety Organizations and Initiatives

The Institute for Safe Medication Practices (ISMP)

ISMP is a non-profit organization devoted entirely to preventing medication errors. They provide crucial resources that pharmacists must be familiar with:

• High-Alert Medications: Drugs that bear a heightened risk of causing significant patient harm when used in error. Examples include:
  • Intravenous anticoagulants (e.g., heparin)
  • Insulin (all formulations)
  • Opioids
  • Neuromuscular blocking agents (e.g., rocuronium)
  • Concentrated electrolytes (e.g., concentrated potassium chloride for injection).
• Safeguards for High-Alert Drugs: Standardizing concentrations, using independent double checks, implementing forcing functions (e.g., removing concentrated KCl from floor stock), and utilizing tall man lettering (e.g., DOPamine vs. DOBUTamine).
• Do Not Crush List: ISMP maintains a list of medications that should not be crushed or chewed, typically because they are extended-release, enteric-coated, or hazardous.

The Joint Commission (TJC) and National Patient Safety Goals (NPSGs)

TJC is an accrediting body for healthcare organizations. To maintain accreditation, institutions must adhere to the NPSGs, which are updated annually to address areas of concern regarding patient safety.

• Key NPSGs Relevant to Pharmacy:
  • Use Medicines Safely: Label all medications on and off the sterile field in perioperative settings. Reduce harm associated with anticoagulation therapy (requires standardized protocols, baseline INR/PTT checks, and patient education).
  • Maintain and Communicate Accurate Patient Medication Information: This mandates formal Medication Reconciliation at all transitions of care (admission, transfer, and discharge) to prevent omissions, duplications, and dosing errors.

Public Health: Immunizations

Pharmacists play a vital role in public health through vaccination advocacy and administration. The Advisory Committee on Immunization Practices (ACIP) provides the gold-standard guidelines for vaccine schedules.

Types of Vaccines

1. Inactivated Vaccines: Utilize a killed version of the pathogen or a fraction of the organism (e.g., toxoids, recombinant proteins). They cannot replicate and therefore cannot cause the disease. Immunity can wane over time, often requiring booster doses.
   • Examples: Influenza (IIV), Pneumococcal (PCV15, PCV20), Tdap, Shingrix (recombinant zoster vaccine).
2. Live Attenuated Vaccines (LAVs): Use a weakened form of the live virus. They replicate in the host to produce a strong, long-lasting immune response.
   • Examples: Measles, Mumps, Rubella (MMR), Varicella, Intranasal Influenza (LAIV), Yellow Fever.
   • Contraindications: LAVs are strictly contraindicated in severely immunocompromised patients (e.g., patients on high-dose systemic corticosteroids, chemotherapy, or with advanced HIV) and pregnant women, due to the risk of uncontrolled viral replication and systemic disease.

Timing and Spacing of Vaccines

• Simultaneous Administration: Most vaccines (both live and inactivated) can be administered at the same clinical visit in different anatomical sites.
• Spacing Between Live Vaccines: If two live vaccines are not administered simultaneously at the same visit, they must be separated by a minimum of 28 days (4 weeks). This prevents the immune response to the first vaccine from neutralizing the second vaccine.
• Spacing Between Inactivated Vaccines: Inactivated vaccines generally do not interfere with each other. There are no minimum spacing requirements between different inactivated vaccines, or between an inactivated and a live vaccine (except in specific cases like PCV/PPSV series timing).
• Tuberculin Skin Testing (TST): Live vaccines can suppress the reactivity to a TST (PPD test), causing a false negative. A TST can be administered on the same day as a live vaccine. However, if a live vaccine was given recently, the TST must be delayed for at least 4 weeks.